Compare ELTK & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | BEAT |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | Israel | United States |
| Employees | N/A | 16 |
| Industry | Electrical Products | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 53.2M |
| IPO Year | 1998 | N/A |
| Metric | ELTK | BEAT |
|---|---|---|
| Price | $9.20 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 8.1K | ★ 610.9K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.30 | $0.54 |
| 52 Week High | $12.19 | $4.00 |
| Indicator | ELTK | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 65.01 | 41.90 |
| Support Level | $8.38 | $0.81 |
| Resistance Level | $9.37 | $1.28 |
| Average True Range (ATR) | 0.53 | 0.07 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 81.43 | 5.62 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.